Edition:
United States

Illumina Inc (ILMN.O)

ILMN.O on Nasdaq

152.31USD
10:02am EDT
Change (% chg)

$1.67 (+1.11%)
Prev Close
$150.64
Open
$150.00
Day's High
$152.33
Day's Low
$149.32
Volume
270,219
Avg. Vol
1,328,170
52-wk High
$220.86
52-wk Low
$127.10

Latest Key Developments (Source: Significant Developments)

Enzo Biochem says Enzo Life Sciences reached settlement with Illumina that included payment of $21 mln to Enzo
Thursday, 7 Jul 2016 08:01am EDT 

Enzo Biochem Inc : Co's unit, Enzo Life Sciences, has reached and finalized a settlement with Illumina that included a payment of $21 million to enzo . Settlement resolving dispute between Enzo Life Sciences and Illumina impacts only one of 11 cases originally brought by enzo .Settlement related to action brought in delaware court by Enzo alleging infringement of patent.  Full Article

Illumina received a product approval certificate for MiSeqDx instrument
Monday, 9 May 2016 04:05pm EDT 

Illumina Inc :Received a product approval certificate for Miseqdx Instrument and Miseqdx universal kit with MFDS in South Korea.  Full Article

Illumina Files Patent Infringement Suit in Switzerland against Genoma SA
Thursday, 21 Apr 2016 04:05pm EDT 

Illumina:Says co and unit Verinata Health, Inc. (together "Illumina"), filed a patent infringement suit against Genoma SA in the Federal Patent Court in Switzerland.Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent (CH) 2 183 693 B1, European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and European Patent (CH) 2 514 842.The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT).Tranquility NIPT service uses the IONA(reg) Test sold by Premaitha Health plc. Illumina previously filed separate suits against Premaitha in the United Kingdom for sale of the IONA Test.  Full Article

Illumina Inc says Francis Desouza appointed president and CEO
Monday, 7 Mar 2016 04:05pm EST 

Illumina Inc:Says Jay Flatley to assume role of executive chairman of the board of directors of Illumina; Francis Desouza appointed president and CEO.Says Francis Desouza, currently president, will be appointed president and chief executive officer.  Full Article

Illumina sues Oxford Nanopore for Patent Infringement
Tuesday, 23 Feb 2016 04:05pm EST 

Illumina:That the company filed lawsuits against Oxford Nanopore Technologies Ltd. and Oxford Nanopore Technologies, Inc. (ONT).The lawsuits were filed concurrently with the U.S. International Trade Commission and in the U.S. District Court for the Southern District of California.Illumina is seeking all available remedies.  Full Article

Biomerieux and Illumina launch Biomerieux EpiSeq
Sunday, 13 Dec 2015 07:00pm EST 

Biomerieux SA:Announced with Illumina the launch of Biomerieux EpiSeq, an next-generation sequencing (NGS) service for epidemiological monitoring and control of healthcare-associated infections.  Full Article

Illumina Inc announces new $250 million share repurchase authorization
Monday, 2 Nov 2015 06:30am EST 

Illumina Inc:Announces new $250 million share repurchase authorization.Says completed repurchase of $96 million under previous share repurchase program.  Full Article

Illumina Inc reaffirms Q4, FY 2015 revenue guidance; updates Q4, FY 2015 EPS guidance
Tuesday, 20 Oct 2015 04:05pm EDT 

Illumina Inc:Says for FY 2015, it projects approximately 18% total revenue growth (21% on a constant currency basis, assuming current rates) and Q4 2015 revenue of approximately $570 million.Updates its projections for non-GAAP earnings per diluted share attributable to Illumina stockholders to $3.29 to $3.31 for FY 2015 and Q4 2015 non-GAAP earnings per diluted share attributable to Illumina stockholders of $0.78 - $0.80.Q4 2015 revenue of $578 million and EPS of $0.86 - Thomson Reuters I/B/E/S.FY 2015 revenue of $2.21 billion and EPS of $3.36 - Thomson Reuters I/B/E/S.  Full Article

Illumina Inc updates FY 2015 revenue outlook; gives Q3 2015 and Q4 2015 revenue outlook
Monday, 5 Oct 2015 04:05pm EDT 

Illumina Inc:Says Estimated Q3 2015 revenue of about $550 million.Says for FY 2015, the company now projects about 18% total revenue growth (21% on a constant currency basis).Expects Q4 2015 revenue of about $570 mln.  Full Article

Illumina Inc and Amoy Diagnostics Co enter strategic collaboration
Wednesday, 30 Sep 2015 08:00pm EDT 

Illumina Inc and Amoy Diagnostics Co:Announce a strategic collaboration to accelerate the adoption of precision medicine and targeted therapies in China.Under the collaboration, Amoy will develop and commercialize a series of oncology-related tests based on Illumina's sequencing (NGS) platforms, including the recently released research use only TruSight Tumor 15 as transferred from Illumina to Amoy.The collaboration reflects the commitment of both companies to provide integrated solutions to meet clinical needs in China.  Full Article

BRIEF-Enzo Biochem says Enzo Life Sciences reached settlement with Illumina that included payment of $21 mln to Enzo

* Co's unit, Enzo Life Sciences, has reached and finalized a settlement with Illumina that included a payment of $21 million to enzo